Etravirine: A Second-Generation NNRTI for Treatment-Experienced Adults With Resistant HIV-1 Infection

Future HIV Therapy
doi 10.2217/17469600.2.6.525
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Efficacy and Safety of Darunavir and Etravirine in an Antiretroviral Multi-Experienced Youth With Vertically HIV-1 Infection

European Journal of Medical Research
Medicine
2009English

Pharmacokinetics of Etravirine Combined With Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

AIDS Research and Treatment
ImmunologyPublic HealthAllergyEnvironmentalDermatologyInfectious DiseasesOccupational Health
2015English

Genotypic Susceptibility Scores and HIV Type 1 RNA Responses in Treatment-Experienced Subjects With HIV Type 1 Infection

AIDS Research and Human Retroviruses
VirologyInfectious DiseasesImmunology
2008English

Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants

Journal of Acquired Immune Deficiency Syndromes
Infectious DiseasesPharmacology
2016English

Raltegravir With Optimized Background Therapy for Resistant HIV-1 Infection

New England Journal of Medicine
Medicine
2008English

Long-Term Efficacy and Safety of Atazanavir/Ritonavir Treatment in a Real-Life Cohort of Treatment-Experienced Patients With HIV Type 1 Infection

AIDS Research and Human Retroviruses
VirologyInfectious DiseasesImmunology
2013English

miR-29a Associates With Viro-Immunological Markers of HIV Infection in Treatment Experienced Patients

Journal of Medical Virology
VirologyInfectious Diseases
2016English

RNA Interference Approaches for Treatment of HIV-1 Infection

Genome Medicine
Molecular MedicineGeneticsMolecular Biology
2015English

Tobacco Use Among Adults Initiating Treatment for HIV Infection in Rural Uganda

AIDS and Behavior
EnvironmentalPublic HealthInfectious DiseasesSocial PsychologyOccupational Health
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy